Abstract
Background: Prostate Cancer (PCa) is the second most common malignancy in UK with highly heterogenous presentation and outcomes. Its heterogeneity poses a significant diagnostic challenge in accurate PCa evaluation. Particularly, as current biomarker, prostate specific antigen (PSA), is not specific or sensitive enough. Nonetheless, non-invasive urine biomarkers seem to have addressed this dilemma and this poster aims to assess their credibility.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
